Cargando…

High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study

Hepatic sinusoidal endothelial injury is a prominent characteristic of liver cirrhosis. We determined plasma soluble thrombomodulin (sTM) levels in cirrhosis patients to evaluate the relationship between vascular injury and long-term prognosis. METHODS: A prospective single-center study was performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Xinhuan, Du, Xiaofei, Liu, Yali, Wu, Jun, Zhang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2022
Materias:	Original Articles: Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528942/ https://www.ncbi.nlm.nih.gov/pubmed/35946457 http://dx.doi.org/10.1097/MEG.0000000000002428

Ejemplares similares

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Higher levels of neutrophil percentage-to-albumin ratio predict increased mortality risk in patients with liver cirrhosis: a retrospective cohort study
por: Du, Xiaofei, et al.
Publicado: (2022)

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study
por: Lee, Nerissa Hoi Ching, et al.
Publicado: (2023)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC
por: Wang, Dong, et al.
Publicado: (2019)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2018)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial)
por: Tripathi, Dhiraj, et al.
Publicado: (2019)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease
por: Konerman, Monica A, et al.
Publicado: (2019)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
por: Middleton, Paul, et al.
Publicado: (2021)

A novel smartphone scleral‐image based tool for assessing jaundice in decompensated cirrhosis patients
por: Kazankov, Konstantin, et al.
Publicado: (2023)

Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
por: Bhatti, Hamza Waqar, et al.
Publicado: (2019)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis
por: Koola, Jejo David, et al.
Publicado: (2019)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
por: Blasco-Algora, Sara, et al.
Publicado: (2016)

Neuroimmunomodulation of adrenoblockers during liver cirrhosis: modulation of hepatic stellate cell activity
por: Medina Pizaño, Mariana Yazmin, et al.
Publicado: (2023)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Lower survival and higher rates of cirrhosis in patients with ROUX-EN-Y gastric bypass hospitalised with alcohol-associated hepatitis
por: Anugwom, Chimaobi, et al.
Publicado: (2023)

Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface
por: McPherson, Stuart, et al.
Publicado: (2023)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Liver cirrhosis in England—an observational study: are we measuring its burden occurrence correctly?
por: Ratib, Sonia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mer7mtbs98b98blt248mdjde9p